Suflave is a drug owned by Braintree Laboratories Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 14, 2044. Details of Suflave's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12239659 | Methods of administering safe colon cleansing compositions |
Jun, 2044
(19 years from now) | Active |
FDA has granted several exclusivities to Suflave. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Suflave, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Suflave.
Exclusivity Information
Suflave holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Suflave's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 15, 2026 |
US patents provide insights into the exclusivity only within the United States, but Suflave is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Suflave's family patents as well as insights into ongoing legal events on those patents.
Suflave's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Suflave's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 14, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Suflave Generics:
There are no approved generic versions for Suflave as of now.
About Suflave
Suflave is a drug owned by Braintree Laboratories Inc. Suflave uses Magnesium Sulfate; Polyethylene Glycol 3350; Potassium Chloride; Sodium Chloride; Sodium Sulfate as an active ingredient. Suflave was launched by Braintree Labs in 2023.
Approval Date:
Suflave was approved by FDA for market use on 15 June, 2023.
Active Ingredient:
Suflave uses Magnesium Sulfate; Polyethylene Glycol 3350; Potassium Chloride; Sodium Chloride; Sodium Sulfate as the active ingredient. Check out other Drugs and Companies using Magnesium Sulfate; Polyethylene Glycol 3350; Potassium Chloride; Sodium Chloride; Sodium Sulfate ingredient
Dosage:
Suflave is available in for solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT | FOR SOLUTION | Prescription | ORAL |